Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Corticosteroids
4 evidence topics · 4 sources
Corticosteroid use and tapering: international consensus guidance
“Once patients achieve treatment goals, the corticosteroid dose should be gradually tapered. In many patients, continuing a low dose of corticosteroids long-term can help to maintain the treatment goal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because corticosteroids may cause transient worsening of myasthenic weakness, it may be appropriate to wait several days for PLEX or IVIg to have a beneficial effect before starting corticosteroids” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroid dosing and combination with a steroid-sparing agent: Nordic guidance
“Early high‐dose oral prednisone or prednisolone is recommended (0.75–1.00 mg/kg) in patients with moderate to severe generalized MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with mild to moderate generalized MG, steroids can be given at lower doses (0.25 mg/kg), followed by gradual escalation depending on the clinical response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A gradual increase of steroid dose from 5 to 10 mg daily over a few weeks is recommended to avoid an initial worsening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 75% of patients, steroids have an effect within 2–4 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the high risk of long‐term adverse effects and to further improve muscle weakness, corticosteroids should be combined with another immunosuppressive drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Daily rather than alternate-day dosing: British guideline update
Glucocorticoid exposure in US commercially insured adults with generalized myasthenia gravis
“Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use of nonsteroidal immunosuppressants was higher among patients with GC use than those without (37.6% any GC use vs 19.6% no GC use).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote